Acute Myeloid Leukemia and Myelodysplastic Syndromes
Stelexis Biosciences Inc. is focused on relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes, with clinical interest centered on difficult-to-treat blood cancers that have limited treatment options after prior therapy.
- Relapsed/refractory AML
- Higher-risk MDS
- Hematologic malignancies
The sponsor’s research activity in this area reflects a therapeutic emphasis on oncology, particularly hematologic oncology and treatment-resistant disease.
Targeted Cancer Therapy
The clinical program includes interest in eganelisib, a targeted agent being studied in both single-agent and combination settings for resistant myeloid cancers.
- Monotherapy development
- Combination therapy
- Signal transduction inhibition
This area highlights a focus on precision-based approaches aimed at addressing malignancies with persistent unmet medical need.
Cytarabine-Based Treatment Strategies
Stelexis Biosciences Inc. also explores cytarabine-containing regimens, with attention to pairing established antileukemic therapy with newer targeted approaches in acute leukemia.
- Cytarabine combinations
- Leukemia treatment regimens
- Salvage therapy
The therapeutic interest lies in improving options for patients whose disease has returned or no longer responds adequately to standard treatment.
Early-Stage Hematology Drug Development
The sponsor’s research activity is concentrated in early clinical development for blood cancer therapies, with attention to safety, tolerability, and preliminary anti-leukemic activity in AML and HR-MDS.
- Early-phase oncology
- Safety and tolerability
- Clinical activity assessment
Its medical interests are centered on advancing therapeutic options within hematology for patients with advanced and refractory disease.
